MEDI or PINK or XBI

Key Takeaways

• Harbor Health Care ETF (MEDI) is an actively managed fund with a concentrated portfolio of approximately 37 holdings focused on global health care companies, carrying a higher expense ratio of 0.80%.
• Simplify Health Care ETF (PINK) offers active management with 50 to 100 U.S. health care holdings, a lower expense ratio of 0.51%, and directs net profits to the Susan G. Komen foundation.
• State Street SPDR S&P Biotech ETF (XBI) is a passive, equal-weighted fund tracking the S&P Biotechnology Select Industry Index, emphasizing biotech stocks with an expense ratio of 0.35% and broader diversification across roughly 160 holdings.
• All three ETFs target the health care sector but differ in active versus passive approaches, geographic scope, and sub-sector emphasis, leading to varying levels of concentration risk and cost efficiency.
• XBI provides the lowest cost and highest liquidity profile, while MEDI and PINK deliver thematic tilts through active stock selection within health care and biotech.
• Structural differences in rebalancing, weighting methodology, and management style influence relative positioning across market cycles in the health care and biotechnology themes.

Introduction

Harbor Health Care ETF (MEDI), Simplify Health Care ETF (PINK), and State Street SPDR S&P Biotech ETF (XBI) represent distinct approaches to health care sector exposure. MEDI and PINK employ active strategies within broader health care, while XBI provides passive, equal-weighted access to biotechnology. These ETFs compete in the same thematic space but offer investors different risk profiles, cost structures, and diversification levels, making them relevant for comparison amid ongoing innovation, regulatory developments, and capital allocation trends in health care.

Harbor Health Care ETF (MEDI) Overview

Harbor Health Care ETF (MEDI) is an actively managed exchange-traded fund launched in November 2022. It seeks long-term capital growth by investing at least 80% of assets in global health care companies involved in research, development, production, or distribution of health care products and services. The fund typically holds around 37 stocks, with top holdings including Eli Lilly & Co., Ascendis Pharma AS, Gilead Sciences Inc., Legend Biotech Corporation, and Rhythm Pharmaceuticals Inc. Sector allocation centers almost entirely on health care. The expense ratio stands at 0.80%. As a non-diversified, actively managed vehicle, it features higher turnover and selective international exposure compared to domestic-focused peers.

Simplify Health Care ETF (PINK) Overview

Simplify Health Care ETF (PINK) is an actively managed fund launched in October 2021. It targets long-term capital appreciation through investments in U.S. health care companies, typically holding 50 to 100 stocks in areas such as biotech, medtech, and gene therapy. The adviser emphasizes companies developing new medicines or improving health care efficiency. Top holdings reflect this focus on innovative names. The expense ratio is 0.51%. A distinguishing feature is its pro bono structure, with net profits donated annually to the Susan G. Komen foundation. The fund maintains quarterly distributions and offers options trading.

State Street SPDR S&P Biotech ETF (XBI) Overview

State Street SPDR S&P Biotech ETF (XBI) is a passively managed fund launched in January 2006 that seeks to track the S&P Biotechnology Select Industry Index. The index applies modified equal weighting to biotechnology companies within the S&P Total Market Index. XBI holds approximately 160 stocks, promoting broad diversification across market capitalizations with reduced single-stock concentration. The expense ratio is 0.35%. Rebalancing occurs quarterly. As a pure-play biotech vehicle with high liquidity and substantial assets under management, it provides efficient, rules-based exposure without active security selection.

Industry and Thematic Landscape

The health care sector encompasses pharmaceuticals, biotechnology, medical devices, and services, driven by aging populations, technological advances in gene therapy and personalized medicine, and evolving regulatory frameworks. Capital flows into innovative sub-sectors remain robust, supported by clinical trial progress and potential policy shifts affecting drug pricing and reimbursement. Macroeconomic factors such as interest rate environments influence growth-oriented biotech valuations, while earnings trends among large pharmaceutical holdings provide stability. Geopolitical and supply-chain considerations affect global exposure in funds like MEDI. Sector risks include clinical failure rates, patent expirations, and heightened scrutiny on pricing and competition.

Performance and Positioning Comparison

In recent market cycles, structural differences have driven varied behaviors. XBI’s equal-weighted biotech focus has exhibited higher volatility and sensitivity to clinical catalysts and interest rate movements, with broader participation across smaller names. MEDI’s concentrated active selection may lead to sharper drawdowns or outperformance depending on manager decisions in global health care. PINK’s active U.S.-centric approach balances innovation exposure with potential stability from established players. Relative positioning reflects trade-offs between XBI’s low-cost diversification and the higher-cost, selective tilts of MEDI and PINK, influencing resilience across recent weeks and months of sector rotation.

AI Screener

Tickeron’s AI Screener is an AI-powered stock and ETF discovery tool that helps traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener helps identify trade ideas, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening. Explore opportunities with the AI Screener today.

Tickeron AI Verdict

Based on observable structural characteristics, Tickeron’s AI would currently assign the highest probabilistic favorability to State Street SPDR S&P Biotech ETF (XBI). Its passive equal-weighted methodology, lowest expense ratio, substantial liquidity, and diversified holdings across the biotechnology segment support more stable risk-adjusted positioning relative to the concentrated active approaches of the other two ETFs. MEDI and PINK offer differentiated thematic execution but carry higher costs and concentration considerations.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations